BACKGROUND/AIMS: Hepatitis C virus (HCV) infection is a global medical problem. The current standard treatment of chronic hepatitis C (CHC), pegylated interferon plus ribavirin, is prolonged, expensive, has serious side effects and, at best, is only 50% effective. Silymarin (SI) is a natural antioxidant often used by patients with CHC, although its efficacy for decreasing HCV levels or ameliorating CHC remains uncertain. HCV infection is associated with increased hepatic oxidative stress, and one of the antioxidant enzymes that protect cells against this stress is haem oxygenase-1 (HO-1). METHODS: We investigated effects of SI on HCV and HO-1 gene expression in Huh-7 cells, CNS3 and 9-13 cells (the latter two stably expressing HCV-proteins). RESULTS: Silymarin significantly downregulated HCV core mRNA (by 20%-36%) and protein (by 30%-60%) in CNS3 cells. In contrast, SI did not decrease HCV NS5A mRNA or protein expression in 9-13 cells. HO-1 mRNA was upregulated (60%-400%) by SI in Huh-7, CNS3 and 9-13 cells, whereas BTB and CNC homology 1 and nuclear factor erythroid related factor 2 mRNA levels were not affected. The effect of SI to downregulate HCV core was not related to changes in the Janus-activated tyrosine kinases-signal transducer and activators of transcription signalling pathway. CONCLUSIONS: Silymarin may be of benefit in CHC, although prospective, randomized, controlled trials are needed to be certain.
BACKGROUND/AIMS: Hepatitis C virus (HCV) infection is a global medical problem. The current standard treatment of chronic hepatitis C (CHC), pegylated interferon plus ribavirin, is prolonged, expensive, has serious side effects and, at best, is only 50% effective. Silymarin (SI) is a natural antioxidant often used by patients with CHC, although its efficacy for decreasing HCV levels or ameliorating CHC remains uncertain. HCV infection is associated with increased hepatic oxidative stress, and one of the antioxidant enzymes that protect cells against this stress is haem oxygenase-1 (HO-1). METHODS: We investigated effects of SI on HCV and HO-1 gene expression in Huh-7 cells, CNS3 and 9-13 cells (the latter two stably expressing HCV-proteins). RESULTS:Silymarin significantly downregulated HCV core mRNA (by 20%-36%) and protein (by 30%-60%) in CNS3 cells. In contrast, SI did not decrease HCV NS5A mRNA or protein expression in 9-13 cells. HO-1 mRNA was upregulated (60%-400%) by SI in Huh-7, CNS3 and 9-13 cells, whereas BTB and CNC homology 1 and nuclear factor erythroid related factor 2 mRNA levels were not affected. The effect of SI to downregulate HCV core was not related to changes in the Janus-activated tyrosine kinases-signal transducer and activators of transcription signalling pathway. CONCLUSIONS:Silymarin may be of benefit in CHC, although prospective, randomized, controlled trials are needed to be certain.
Authors: Michiari Okuda; Kui Li; Michael R Beard; Lori A Showalter; Frank Scholle; Stanley M Lemon; Steven A Weinman Journal: Gastroenterology Date: 2002-02 Impact factor: 22.682
Authors: Daniel Martin; Ana I Rojo; Marta Salinas; Raquel Diaz; German Gallardo; Jawed Alam; Carlos M Ruiz De Galarreta; Antonio Cuadrado Journal: J Biol Chem Date: 2003-12-19 Impact factor: 5.157
Authors: Leonard B Seeff; Teresa M Curto; Gyongyi Szabo; Gregory T Everson; Herbert L Bonkovsky; Jules L Dienstag; Mitchell L Shiffman; Karen L Lindsay; Anna S F Lok; Adrian M Di Bisceglie; William M Lee; Marc G Ghany Journal: Hepatology Date: 2008-02 Impact factor: 17.425
Authors: Johannes G Bode; Stephan Ludwig; Christina Ehrhardt; Ute Albrecht; Andreas Erhardt; Fred Schaper; Peter C Heinrich; Dieter Häussinger Journal: FASEB J Date: 2003-01-22 Impact factor: 5.191
Authors: N D Freedman; T M Curto; C Morishima; L B Seeff; Z D Goodman; E C Wright; R Sinha; J E Everhart Journal: Aliment Pharmacol Ther Date: 2010-11-02 Impact factor: 8.171
Authors: Roy L Hawke; Sarah J Schrieber; Tedi A Soule; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Josh Berman; Qi-Ying Liu; Edward Doo; Michael W Fried Journal: J Clin Pharmacol Date: 2009-10-19 Impact factor: 3.126
Authors: Michael W Fried; Victor J Navarro; Nezam Afdhal; Steven H Belle; Abdus S Wahed; Roy L Hawke; Edward Doo; Catherine M Meyers; K Rajender Reddy Journal: JAMA Date: 2012-07-18 Impact factor: 56.272
Authors: Jessica Wagoner; Amina Negash; Olivia J Kane; Laura E Martinez; Yaakov Nahmias; Nigel Bourne; David M Owen; Joe Grove; Claire Brimacombe; Jane A McKeating; Eve-Isabelle Pécheur; Tyler N Graf; Nicholas H Oberlies; Volker Lohmann; Feng Cao; John E Tavis; Stephen J Polyak Journal: Hepatology Date: 2010-06 Impact factor: 17.425